Omega Healthcare: Attractive For The Near 6% Yield, But Don't Expect Meaningful Upside (Rating Downgrade)

Summary Omega Healthcare Investors is downgraded from buy to hold as growth appears fully priced in near current levels. OHI delivered strong Q2 results, with AFFO guidance raised to $3.22–$3.26 and a 4.2% growth rate amid challenging conditions. Balance sheet strength is notable, with net debt to EBITDA at 3.3x and an 87% FAD payout ratio supporting a secure 5.71% dividend yield. Near-term upside is limited; a more attractive entry point may emerge if shares pull back toward $40 amid macro risks. Looking for more investing ideas like this one? Get them exclusively at iREIT®+HOYA Capital. Learn More » Pla2na/iStock via Getty Images Introduction The REIT ( XLRE ) sector has been under some pressure recently, primarily due to the spike in long-term Treasury yields. The 10-year treasury ( US10Y ) recently hit 5% for the first time in nearly three years, signaling there This article was written by Dividend Collection Agency 9.73K Followers Follow Formerly known as "The Dividend Collectuh." Top 1% of financial experts on TipRanks. Contributing analyst to the iREIT+Hoya Capital investment group. Dividend Collection Agency is not a registered investment professional nor financial advisor and these articles should not be taken as financial advice. This is for educational purposes only and I encourage everyone to do their own due diligence. I'm a Navy veteran who enjoys dividend investing in quality blue-chip stocks, BDCs, and REITs. I am a buy-and-hold investor who prefers quality over quantity and plans to supplement his retirement income and live off dividends in the next 5-7 years. I aspire to reach and help the hard working, lower and middle class workers build investment portfolios of high quality, dividend-paying companies. I also hope to give investors a new perspective to help them reach financial independence. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.